BACKGROUND/AIMS: Angiotensin II (Ang II) mediates progressive nephron loss in diabetes and stimulates apoptotic cell death in several tissues. We studied the extent of apoptosis in streptozotocin (STZ) induced diabetic nephropathy in the rat and the effects of insulin and type 1 (AT1) or type 2 (AT2) Ang II receptor blockade with losartan or PD123319, respectively. METHODS: Three groups of rats were studied after 2 and 12 weeks: (1) controls; (2) STZ-diabetic rats (STZ rats), and (3) STZ-diabetic rats with insulin implants. Additional rats were treated with losartan (25 mg/kg/day) and/or PD123319 (10 mg/kg/day) for 2 weeks. Kidneys were examined for apoptosis, using the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, DNA laddering, and electron microscopy. Immunoblotting determined expression of the proapoptotic protein Bax and of the antiapoptotic protein Bcl-2 in proximal tubules. RESULTS: Diabetes caused a significant increase in apoptosis, involving tubular and interstitial cells of cortex and medulla, but not glomerular cells (2 weeks: controls 264 +/- 94 vs. STZ rats 1,501 +/- 471 apoptotic nuclei/kidney section; p < 0.02; n = 6-8), an effect reversed by insulin. In STZ rats, ultrastructural examination revealed chromatin condensation and nuclear fragmentation in tubular and interstitial cells. At 2 and 12 weeks, a significant decrease in the expression of the antiapoptotic protein Bcl-2 occurred in STZ rat proximal tubules, with restoration by insulin. In STZ rats, treatment for 2 weeks with losartan or PD123319 inhibited apoptosis in the kidneys, with no additive effect of the combination therapy. CONCLUSIONS: Apoptosis occurs in diabetic nephropathy, involving tubular and interstitial cells, an effect reversed by insulin therapy. Furthermore, the effects of AT1 or AT2 receptor blockade suggest that Ang II is involved in mediating apoptosis in the diabetic kidney. Copyright 2004 S. Karger AG, Basel
BACKGROUND/AIMS: Angiotensin II (Ang II) mediates progressive nephron loss in diabetes and stimulates apoptotic cell death in several tissues. We studied the extent of apoptosis in streptozotocin (STZ) induced diabetic nephropathy in the rat and the effects of insulin and type 1 (AT1) or type 2 (AT2) Ang II receptor blockade with losartan or PD123319, respectively. METHODS: Three groups of rats were studied after 2 and 12 weeks: (1) controls; (2) STZ-diabeticrats (STZrats), and (3) STZ-diabeticrats with insulin implants. Additional rats were treated with losartan (25 mg/kg/day) and/or PD123319 (10 mg/kg/day) for 2 weeks. Kidneys were examined for apoptosis, using the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, DNA laddering, and electron microscopy. Immunoblotting determined expression of the proapoptotic protein Bax and of the antiapoptotic protein Bcl-2 in proximal tubules. RESULTS:Diabetes caused a significant increase in apoptosis, involving tubular and interstitial cells of cortex and medulla, but not glomerular cells (2 weeks: controls 264 +/- 94 vs. STZrats 1,501 +/- 471 apoptotic nuclei/kidney section; p < 0.02; n = 6-8), an effect reversed by insulin. In STZrats, ultrastructural examination revealed chromatin condensation and nuclear fragmentation in tubular and interstitial cells. At 2 and 12 weeks, a significant decrease in the expression of the antiapoptotic protein Bcl-2 occurred in STZrat proximal tubules, with restoration by insulin. In STZrats, treatment for 2 weeks with losartan or PD123319 inhibited apoptosis in the kidneys, with no additive effect of the combination therapy. CONCLUSIONS: Apoptosis occurs in diabetic nephropathy, involving tubular and interstitial cells, an effect reversed by insulin therapy. Furthermore, the effects of AT1 or AT2 receptor blockade suggest that Ang II is involved in mediating apoptosis in the diabetic kidney. Copyright 2004 S. Karger AG, Basel
Authors: Gang Yuan; Juanjuan Deng; Tao Wang; Chunxia Zhao; Xizheng Xu; Peihua Wang; James W Voltz; Matthew L Edin; Xiao Xiao; Lee Chao; Julie Chao; Xin A Zhang; Darryl C Zeldin; Dao Wen Wang Journal: Endocrinology Date: 2007-02-01 Impact factor: 4.736
Authors: Marie-Luise Brezniceanu; Cara J Lau; Nicolas Godin; Isabelle Chénier; Alain Duclos; Jean Ethier; Janos G Filep; Julie R Ingelfinger; Shao-Ling Zhang; John S D Chan Journal: J Am Soc Nephrol Date: 2010-03-18 Impact factor: 10.121
Authors: Chao-Sheng Lo; Fang Liu; Yixuan Shi; Hasna Maachi; Isabelle Chenier; Nicolas Godin; Janos G Filep; Julie R Ingelfinger; Shao-Ling Zhang; John S D Chan Journal: Am J Physiol Renal Physiol Date: 2011-12-28
Authors: Maria Dolores Sanchez-Niño; Ana Belen Sanz; Corina Lorz; Andrea Gnirke; Maria Pia Rastaldi; Viji Nair; Jesus Egido; Marta Ruiz-Ortega; Matthias Kretzler; Alberto Ortiz Journal: J Am Soc Nephrol Date: 2010-01-28 Impact factor: 10.121
Authors: Monika A Niewczas; Linda H Ficociello; Amanda C Johnson; William Walker; Elizabeth T Rosolowsky; Bijan Roshan; James H Warram; Andrzej S Krolewski Journal: Clin J Am Soc Nephrol Date: 2008-12-10 Impact factor: 8.237
Authors: Aydın Güçlü; Haydar Ali Erken; Gülten Erken; Yavuz Dodurga; Arzu Yay; Özge Özçoban; Hasan Şimşek; Aydın Akçılar; Fatma Emel Koçak Journal: Int Urol Nephrol Date: 2015-11-27 Impact factor: 2.370
Authors: Corina Lorz; Alberto Benito-Martín; Anissa Boucherot; Alvaro C Ucero; Maria Pia Rastaldi; Anna Henger; Silvia Armelloni; Beatriz Santamaría; Celine C Berthier; Matthias Kretzler; Jesus Egido; Alberto Ortiz Journal: J Am Soc Nephrol Date: 2008-02-20 Impact factor: 10.121